Mostrar el registro sencillo del ítem

dc.contributor.authorZapata Cachafeiro, Maruxa*
dc.contributor.authorPrieto-Campo, Á.*
dc.contributor.authorPortela Romero, Manuel *
dc.contributor.authorCarracedo Martínez, Eduardo *
dc.contributor.authorLema Oreiro, Martina*
dc.contributor.authorPiñeiro Lamas, María*
dc.contributor.authorChaudhuri, S.*
dc.contributor.authorSalgado Barreira, Angel *
dc.contributor.authorFigueiras Guzmán, Adolfo*
dc.date.accessioned2025-09-09T10:23:33Z
dc.date.available2025-09-09T10:23:33Z
dc.date.issued2023
dc.identifier.citationZapata-Cachafeiro M, Prieto-Campo Á, Portela-Romero M, Carracedo-Martínez E, Lema-Oreiro M, Piñeiro-Lamas M, et al. Effect of Previous Anticoagulant Treatment on Risk of COVID-19. Drug Safety. 2023;46(3):273-81.
dc.identifier.issn1179-1942
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/63b996e24386723d2da3790c
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21395
dc.description.abstractIntroduction: Little is known about the role played by anticoagulants in COVID-19. Objective: The aim of this study was to assess the impact of previous anticoagulant treatment on risk of hospitalization due to COVID-19, progression to severe COVID-19 and susceptibility to COVID-19 infection. Methods: We conducted a multiple population-based case-control study in northwest Spain, in 2020, to assess (1) risk of hospitalization: cases were all patients admitted due to COVID-19 with PCR confirmation, and controls were a random matched sample of subjects without a positive PCR; (2) progression: cases were hospitalized COVID-19 subjects, and controls were all non-hospitalized COVID-19 patients; and (3) susceptibility: cases were patients with a positive PCR (hospitalized and non-hospitalized), and the controls were the same as for the hospitalization model. Adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using a generalized linear mixed model. Results: The consumption of antivitamin K and direct-acting anticoagulants apparently was not associated with the risk of progression to severe COVID-19 (OR 0.93 [95% CI 0.74-1.17] and OR 1.04 [95% CI 0.79-1.36], respectively). Antivitamin K anticoagulants were associated with a significantly lower risk of hospitalization (OR 0.77 [95% CI 0.64-0.93]), which, in part, can be explained by a decreased risk of susceptibility to infection (OR 0.83 [95% CI 0.74-0.92]). The use of direct-acting anticoagulants was not associated with the risk of hospitalization, although it also seems to decrease susceptibility (OR 0.85 [95% CI 0.74-0.98]). It has also been observed that low-molecular-weight heparins were associated with an increased risk of progression to severe COVID-19 (OR 1.25 [95% CI 1.01-1.55]). Conclusion: The results of this study have shown that antivitamin K anticoagulants and direct-acting anticoagulants do not increase the risk of progression to more severe stages. Antivitamin K consumption was associated with a lower risk of hospitalization and susceptibility to infection.
dc.languageeng
dc.rightsAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.meshHumans *
dc.subject.meshAnticoagulants *
dc.subject.meshCOVID-19 *
dc.subject.meshCase-Control Studies *
dc.subject.meshRisk Factors *
dc.subject.meshHospitalization *
dc.titleEffect of Previous Anticoagulant Treatment on Risk of COVID-19
dc.typeArtigo
dc.authorsophosZapata-Cachafeiro, M.; Prieto-Campo, Á.; Portela-Romero, M.; Carracedo-Martínez, E.; Lema-Oreiro, M.; Piñeiro-Lamas, M.; Chaudhuri, S.; Salgado-Barreira, Á.; Figueiras, A.
dc.identifier.doi10.1007/s40264-022-01266-0
dc.identifier.sophos63b996e24386723d2da3790c
dc.issue.number3
dc.journal.titleDrug Safety*
dc.organizationInstituto de Investigación Sanitaria de Santiago de Compostela (IDIS)
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Atención Primaria Santiago::Atención primaria
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Atención Primaria Santiago::Atención primaria
dc.organizationDirección Xeral de Asistencia Sanitaria
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Vigo::Unidade de investigación
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)
dc.page.initial273
dc.page.final281
dc.relation.publisherversionhttps://doi.org/10.1007/s40264-022-01266-0
dc.rights.accessRightsopenAccess*
dc.subject.keywordIDIS
dc.subject.keywordAS Santiago
dc.subject.keywordAS Santiago AP
dc.subject.keywordAS Santiago
dc.subject.keywordAS Santiago AP
dc.subject.keywordDXAS
dc.subject.keywordAS Santiago
dc.subject.keywordIDIS
dc.subject.keywordAS Vigo
dc.subject.keywordCHUVI
dc.subject.keywordAS Santiago
dc.subject.keywordIDIS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number46


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)